The effects of tetramethylpyrazine on the incidence of arrhythmias and the release of PGI2 and TXA2 in the ischemic rat heart.

Pretreatment with tetramethylpyrazine (TMP, 12 mg/kg/day), a drug originally derived from the rhizomes of Ligusticum wallichii, significantly reduced the incidence of ischemia-induced ventricular tachycardia (VT) and fibrillation (VF) from 100% and 50% of control hearts to 41% (p < 0.05) and 0% (p < 0.05), respectively, in the ischemic rat heart. TMP also diminished the incidence of reperfusion-induced VT and VF from 100% and 100% of control hearts to 33% (p < 0.05) and 41% (p < 0.05), respectively. Pretreatment with TMP produced a slight, but significant increase of 6-keto-PGF1 alpha and a decrease of TXB2 production during aerobic perfusion. Ischemia and reperfusion markedly increased the release of 6-keto-PGF1 alpha and TXB2. Pretreatment with TMP significantly enhanced the release of 6-keto-PGF1 alpha and diminished TXB2 outflow following left coronary artery occlusion and reperfusion.
AuthorsJ Feng, G Wu, S Tang
JournalPlanta medica (Planta Med) Vol. 65 Issue 3 Pg. 268-70 (Apr 1999) ISSN: 0032-0943 [Print] GERMANY
PMID10232078 (Publication Type: Letter)
Chemical References
  • Pyrazines
  • Thromboxane A2
  • Epoprostenol
  • tetramethylpyrazine
  • Animals
  • Arrhythmias, Cardiac (prevention & control)
  • Epoprostenol (metabolism)
  • Heart (drug effects)
  • Male
  • Myocardial Ischemia (metabolism)
  • Pyrazines (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Thromboxane A2 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: